Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Texas
Clinical trial register · United States · industry-sponsored

Clinical Trials in Texas, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9125 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 08 Oct 2026, 03:16 UTC
9125
Studies in scope
industry-sponsored, all four open statuses
4951
Recruiting now
open to new participants
2192
Lead sponsors
across recruiting studies
Top states
California 113 Florida 110 Massachusetts 66 Georgia 63 Illinois 62
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca53 Novartis Pharmaceuticals44 Eli Lilly and Company33 Merck Sharp & Dohme LLC31 GlaxoSmithKline31 Clear sponsor filter
State
California113 Florida110 Massachusetts66 Georgia63 Illinois62
All 47 states
Target enrolment
to

Trials with a site in Texas

44 of 9125 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis
NCT07801495Moderate to Severe Psoriatic Arthritis
DrugDDY391
Novartis Pharmaceuticals
Phase 2
220
Texas
2026-10-14
Recruiting
A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
NCT07737743Sjögren's Disease
DrugDDY391
Novartis Pharmaceuticals
Phase 2
344
Florida, Illinois, Oklahoma, Pennsylvania, Texas
2026-08-24
Recruiting
A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
NCT07700056Chronic Pruritus of Unknown Origin
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
180
Florida, Georgia, Indiana, New York, Ohio, South Carolina, Texas
2026-08-24
Recruiting
A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)
NCT07681271Papulopustular Rosacea
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 2
100
Texas
2026-07-30
Recruiting
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
NCT07564401Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Novartis Pharmaceuticals
Phase 1/2
80
Kentucky, Texas, Washington
2026-06-16
Recruiting
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation
NCT07626281Inclisiran Formulation
DrugInclisiran
Novartis Pharmaceuticals
Phase 1
152
Kansas, Texas, Utah
2026-06-09
Recruiting
Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer
NCT07604571Advanced HR+/HER2- Breast Cancer
DrugsLetrozole·Fulvestrant
Novartis Pharmaceuticals
Phase 1
194
Connecticut, Texas
2026-05-28
Recruiting
A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
NCT07570979Metastatic Castration-resistant Prostate Cancer (mCRPC)
DrugsAbiraterone·Enzalutamide
Novartis Pharmaceuticals
Phase 1
208
Massachusetts, Texas
2026-05-25
Recruiting
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07441642Geographic Atrophy Secondary to Age-related Macular Degeneration
Novartis Pharmaceuticals
Phase 2
272
California, Florida, Massachusetts, New Jersey, New York, Pennsylvania, Texas
2026-03-09
Recruiting
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
NCT07288359Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
DrugsLetrozole·Fulvestrant
Novartis Pharmaceuticals
Phase 1/2
205
Georgia, Tennessee, Texas
2025-12-29
Recruiting
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
NCT07226986PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
DrugsAbiraterone·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
123
California, Texas, Utah
2025-12-05
Recruiting
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
NCT06997588PIK3CA-related Overgrowth Spectrum (PROS)
DrugAlpelisib
Novartis Pharmaceuticals
Phase 2
140
Missouri, North Carolina, Ohio, Oregon, Pennsylvania, Texas, Washington
2025-10-09
Recruiting
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
NCT06858319Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases, Glomerulonephritis
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
220
Colorado, Florida, Iowa, New York, Tennessee, Texas
2025-07-28
Recruiting
DFT383 in Pediatric Participants With Nephropathic Cystinosis
NCT06910813Nephropathic Cystinosis
Novartis Pharmaceuticals
Phase 1/2
30
Arizona, California, Georgia, Pennsylvania, Texas
2025-06-02
Recruiting
A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.
NCT06632600Chagas Disease
DrugLXE408
Novartis Pharmaceuticals
Phase 2
130
California, Florida, Massachusetts, Texas
2025-04-28
Active, closed
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
NCT06704269Generalized Myasthenia Gravis
Novartis Pharmaceuticals
Phase 1/2
15
California, North Carolina, Pennsylvania, Texas
2025-04-22
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
DrugsRibociclib·Fulvestrant
Novartis Pharmaceuticals
Phase 1/2
280
California, Florida, Massachusetts, Missouri, New York, Tennessee, Texas, Washington
2025-04-03
Recruiting
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
NCT06797518Glomerulonephritis, IGA, Immunoglobulin A Nephropathy
DrugIptacopan
Novartis Pharmaceuticals
Phase 2
20
Alabama, California, Florida, Georgia, Idaho, Nevada, Ohio, Texas
2025-02-21
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
21
Alabama, Florida, Georgia, Illinois, Iowa, North Carolina, Pennsylvania, Texas
2024-12-17
Recruiting
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
NCT06562192Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
Novartis Pharmaceuticals
Phase 1
162
Alabama, California, Florida, Massachusetts, Michigan, Minnesota, Texas, Washington
2024-10-15
Recruiting
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
NCT06546670Sickle Cell Disease
Novartis Pharmaceuticals
Phase 1/2
161
Alabama, Florida, Massachusetts, North Carolina, Pennsylvania, Rhode Island, Texas
2024-08-15
Active, closed
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
NCT06247995Breast Cancer
DrugsGa-NeoB·Lu-NeoB·Capecitabine
Novartis Pharmaceuticals
Phase 1/2
20
California, Minnesota, Texas, Wisconsin
2024-08-14
Active, closed
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
NCT06331312Polymyalgia Rheumatica
DrugSecukinumab
Novartis Pharmaceuticals
Phase 3
162
Arizona, California, Florida, Maryland, Michigan, New Hampshire, Ohio, Texas
2024-06-28
Recruiting
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
NCT05868629Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
Novartis Pharmaceuticals
Observational
40
California, Colorado, District of Columbia, North Carolina, Ohio, Tennessee, Texas
2024-02-06
Active, closed
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
NCT05849298Prostatic Neoplasm
DrugsARPI·Pylarify·Illuccix·Lu-PSMA
Novartis Pharmaceuticals
Phase 2
49
Colorado, Georgia, Indiana, Iowa, Nebraska, Oregon, Pennsylvania, Texas
2024-01-03
Active, closed
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
NCT05870579Breast Cancer
DrugsGa-NeoB·Lu-NeoB·Ribociclib·Fulvestrant
Novartis Pharmaceuticals
Phase 1
28
California, Texas
2023-11-13
Active, closed
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
NCT05838768MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
DrugsIrinotecan·Pembrolizumab
Novartis Pharmaceuticals
Phase 1
123
California, Massachusetts, New York, Texas
2023-06-27
Active, closed
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
NCT05456191Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
DrugsAsciminib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 3
568
Colorado, Illinois, Minnesota, North Carolina, Ohio, Oregon, Texas, Virginia
2022-11-21
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 4
347
Michigan, New York, Oregon, Texas, Wisconsin
2022-08-30
Active, closed
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
NCT05109728Glioblastoma
Drugs[177Lu]Lu-DOTA-TATE·[68Ga]Ga-DOTA-TATE·Lutathera
Novartis Pharmaceuticals
Phase 1
63
New York, Pennsylvania, Texas, Wisconsin
2022-05-10
Recruiting
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
NCT04925479Myeloid Leukemia, Philadelphia Positive
DrugABL001
Novartis Pharmaceuticals
Phase 1/2
34
Indiana, Massachusetts, Mississippi, New York, Ohio, Pennsylvania, Texas, Utah
2021-12-27
Active, closed
A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors
NCT04857372Mesothelioma
Novartis Pharmaceuticals
Phase 1
137
California, Illinois, Massachusetts, Ohio, Texas
2021-10-21
Recruiting
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
NCT04657822Sickle Cell Disease
DrugCrizanlizumab
Novartis Pharmaceuticals
Phase 4
130
Alabama, District of Columbia, Georgia, North Carolina, Pennsylvania, Texas
2021-06-10
Active, closed
Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum
NCT04589650PIK3CA-related Overgrowth Spectrum (PROS)
DrugAlpelisib
Novartis Pharmaceuticals
Phase 2
236
California, Colorado, Missouri, New York, North Carolina, Ohio, Pennsylvania, Texas
2021-04-19
Active, closed
Atrasentan in Patients With Proteinuric Glomerular Diseases
NCT04573920IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease
DrugAtrasentan
Novartis Pharmaceuticals
Phase 2
103
California, Colorado, Louisiana, Massachusetts, Minnesota, Nevada, North Carolina, Texas
2021-03-15
Active, closed
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
DrugsTNO155·Opnurasib·Tislelizumab
Novartis Pharmaceuticals
Phase 1/2
344
Georgia, Massachusetts, Pennsylvania, Texas
2021-02-24
Active, closed
Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations
NCT04641442NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations
DrugArumakimig
Novartis Pharmaceuticals
Phase 2
17
Ohio, Pennsylvania, Texas, Washington
2020-12-18
Active, closed
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
NCT04417621Melanoma
DrugsNaporafenib·Trametinib·Ribociclib
Novartis Pharmaceuticals
Phase 2
134
California, Florida, Massachusetts, Minnesota, New York, Pennsylvania, Texas
2020-10-30
Active, closed
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments
NCT04058756Advanced Solid Tumors
DrugSpartalizumab
Novartis Pharmaceuticals
Phase 1
120
New York, Oregon, Texas
2019-10-30
Active, closed
Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients
NCT03814746Sickle Cell Disease (SCD)
DrugCrizanlizumab
Novartis Pharmaceuticals
Phase 3
254
Georgia, Massachusetts, North Carolina, Tennessee, Texas
2019-07-26
Active, closed
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
NCT03960840Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia
DrugIbrutinib
Novartis Pharmaceuticals
Phase 1/2
217
California, Florida, Illinois, Kansas, Massachusetts, Pennsylvania, Tennessee, Texas
2019-06-26
Recruiting
Dabrafenib and/or Trametinib Rollover Study
NCT03340506Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
100
Arizona, Maryland, Ohio, Texas
2018-01-26
Active, closed
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
NCT02381886Advanced Malignancies That Harbor IDHR132 Mutations
Novartis Pharmaceuticals
Phase 1
166
Massachusetts, New York, Texas
2015-03-06
Active, closed
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
NCT01872260Breast Cancer
DrugsAlpelisib·Ribociclib·Letrozole
Novartis Pharmaceuticals
Phase 1/2
259
California, Florida, Massachusetts, Tennessee, Texas, Washington
2013-10-22
Rows per page Showing 1–44 of 44
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 October 2026. https://priyalifescience.com/clinical-trials-usa/state/texas

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,125 studies in total at the last sync on 08 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 44 of those studies with a site in Texas that also match the filters currently applied.

How many clinical trials are recruiting in Texas?

24 of the 44 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 20 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Texas), 44 studies
PhaseStudiesRecruitingShare
Phase 213729.5%
Phase 1/212727.3%
Phase 110422.7%
Phase 35211.4%
Phase 4336.8%
Observational112.3%

Most active sponsors

Lead sponsors with the most studies (Texas)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals4424
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.